<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="passed on during cell division, enabling quick, efficient and high-throughput" exact="testing" post="of drug candidates that act on viral transcription, translation"/>
 <result pre="combat infectious diseases. Vaccines have been successful in dramatically lowering" exact="infection" post="rates for diseases like measles, mumps, rubella, diphtheria, pertussis"/>
 <result pre="NS5A and NS5B. Most HCV strains will not establish productive" exact="infection" post="in cell culture and it was not until 2005"/>
 <result pre="1a, 1b, 2, 3, 4, 5a and 6a to ensure" exact="testing" post="of pan-genotype effectiveness of drug candidates 30, 31, 32,"/>
 <result pre="be fatal. To date, there is no approved specific drug" exact="treatment" post="available against dengue virus [38]. Dengue virus has a"/>
 <result pre="tested a HCV compound library in a high-throughput DENV2 replicon" exact="screening" post="assay, identifying JNJ-1A as an effective lead [49]. This"/>
 <result pre="showing that it was effective in alleviating symptoms of CHIKV" exact="infection" post="in a mouse model [66]. However, no clinical studies"/>
 <result pre="antibody targeting the viral fusion protein, have been approved for" exact="treatment" post="and prevention of RSV [74]. RSV is a member"/>
 <result pre="F in trans, and transferred to different cell lines by" exact="infection" post="with resulting trans-packaged VLPs (Fig. 1d) [78]. This replicon"/>
 <result pre="1d) [78]. This replicon system was then used in high-throughput" exact="screening" post="for specific anti-RSV drugs acting on the replication machinery"/>
 <result pre="world [85]. Despite very high virus titers in stools during" exact="infection" post="and successful culture of murine noroviruses in RAW264.7 and"/>
 <result pre="rationally designs protease inhibitors of norovirus and other viruses, and" exact="tests" post="compounds using replicon systems (reviewed in Ref. [93]). Four"/>
 <result pre="Updates Blueprint List of Priority Diseases. Available at: https://globalbiodefense.com/2018/02/12/who-updates-blueprint-list-of-priority-diseases/. 13BasuA.High-throughput" exact="screening" post="of viral entry inhibitors using pseudotyped virusCurr. Protoc. Pharmacol.132010B.3"/>
 <result pre="therapiesPharm. Ther.422017316329 25European Association for Study of LiverEASL recommendations on" exact="treatment" post="of hepatitis C 2015J. Hepatol.63201519923625911336 26WakitaT.Production of infectious hepatitis"/>
 <result pre="cultureScience309200562362615947137 28VenkatramanS.Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for" exact="treatment" post="of chronic hepatitis C infectionsTrends Pharmacol. Sci.33201228929422521415 29KwongA.D.Discovery and"/>
 <result pre="ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the" exact="treatment" post="of hepatitis C virus infectionJ. Med. Chem.5720142033204624320933 37GentileI.The discovery"/>
 <result pre="encephalitisAnnu. Rev. Entomol.49200414117414651460 56LundströmJ.O.Sindbis virus polyarthritis outbreak signalled by virus" exact="prevalence" post="in the mosquito vectorsPLoS Negl. Trop. Dis.132019e0007702 57RuppJ.C.Alphavirus RNA"/>
 <result pre="mutations in a Sindbis virus variant able to establish persistent" exact="infection" post="in BHK cells: the importance of a mutation in"/>
 <result pre="82WangG.Discovery of 4’-chloromethyl-2’-deoxy-3’,5’-di-O-isobutyryl-2’-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for" exact="treatment" post="of human respiratory syncytial virus infectionJ. Med. Chem.5820151862187825667954 83J&amp;amp;J"/>
 <result pre="role of noroviruses in sporadic gastroenteritisEmerg. Infect. Dis.1420081224123118680645 86StraubT.M.Human norovirus" exact="infection" post="of caco-2 cells grown as a three-dimensional tissue structureJ."/>
</results>
